Table 2.

Treatment-emergent adverse events

Event	All Participants (n = 300)
Any Adverse Event, n (%)	220 (73.3%)
Serious Adverse Events, n (%)	1 (0.3%)
Adverse Events Leading to Treatment Discontinuation, n (%)	41 (13.7%)
*Most Frequent Adverse Events Leading to Treatment Discontinuation
Constipation, n (%)	22 (7.3%)
*Most Frequent Any Adverse Event
Constipation, n (%)	124 (41.3%)
Injection site reaction, n (%)	29 (9.7%)
Nausea, n (%)	22 (7.3%)
Fatigue, n (%)	20 (6.7%)
Aggravation of migraine, n (%)	14 (4.7%)
Tinnitus, n (%)	14 (4.7%)
Alopecia, n (%)	11 (3.7%)
Muscle cramps, n (%)	11 (3.7%)
Dizziness, n (%)	10 (3.3%)
Abdominal pain, n (%)	9 (3%)
Insomnia, n (%)	8 (2.7%)
Metrorrhagia, n (%)	6 (2%)
Weight gain, n (%)	6 (2%)
Hot flashes, n (%)	6 (2%)
Flushing, n (%)	6 (2%)

^*Adverse events occurring in ≥ 2% of participants